Aperture Venture Partners

Shoulder Innovations designs and manufactures medical devices for shoulder replacement surgery, focusing on inset glenoid fixation technology to provide a stable glenoid platform and reliable fixation. Its product portfolio includes InSet Total Shoulder Arthroplasty, InSet Reverse Shoulder Arthroplasty, ProVoyance Shoulder Planning Software, and InSet Tray System, along with associated instrumentation. The company distributes its products through partners in the United States and aims to reduce operative time and overall healthcare costs while improving post-surgical implant stability. Founded in 2009, the company is based in Holland, Michigan.

XII Medical is a medical device developer focused on addressing obstructive sleep apnea through innovative technology. The company specializes in creating a minimally invasive outpatient solution that utilizes an implantable neurostimulation device. This device functions by preventing the muscles in the throat from relaxing during sleep, thereby avoiding airway blockage. By enhancing oropharyngeal airflow, XII Medical aims to provide patients with a proactive approach to managing their sleep apnea, improving their overall quality of life.

Miach Orthopaedics is a medical device company based in Westborough, Massachusetts, specializing in the development of bio-engineered surgical implants aimed at promoting new tissue growth and aiding in connective tissue repair. Founded in 2016, the company focuses on its innovative Bridge-Enhanced ACL Repair technology, which serves as an alternative to traditional anterior cruciate ligament (ACL) reconstruction. This technology provides surgeons with a method to restore the normal anatomy and function of the knee for patients who have experienced ACL injuries, offering a promising option for recovery and rehabilitation.

Nalu Medical is an early-stage company based in Carlsbad, California, focused on developing innovative medical devices to enhance the treatment of chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator that is cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS). Nalu Medical's neurostimulation devices leverage neuromodulation technology to offer a variety of therapeutic options aimed at alleviating chronic pain, thereby improving the quality of life for patients.

Shoulder Innovations designs and manufactures medical devices for shoulder replacement surgery, focusing on inset glenoid fixation technology to provide a stable glenoid platform and reliable fixation. Its product portfolio includes InSet Total Shoulder Arthroplasty, InSet Reverse Shoulder Arthroplasty, ProVoyance Shoulder Planning Software, and InSet Tray System, along with associated instrumentation. The company distributes its products through partners in the United States and aims to reduce operative time and overall healthcare costs while improving post-surgical implant stability. Founded in 2009, the company is based in Holland, Michigan.

XII Medical is a medical device developer focused on addressing obstructive sleep apnea through innovative technology. The company specializes in creating a minimally invasive outpatient solution that utilizes an implantable neurostimulation device. This device functions by preventing the muscles in the throat from relaxing during sleep, thereby avoiding airway blockage. By enhancing oropharyngeal airflow, XII Medical aims to provide patients with a proactive approach to managing their sleep apnea, improving their overall quality of life.

Nalu Medical is an early-stage company based in Carlsbad, California, focused on developing innovative medical devices to enhance the treatment of chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator that is cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS). Nalu Medical's neurostimulation devices leverage neuromodulation technology to offer a variety of therapeutic options aimed at alleviating chronic pain, thereby improving the quality of life for patients.

V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

Neuros Medical, Inc. is a neuromodulation company dedicated to developing innovative therapies to address unmet medical needs for patients globally. Founded in 2008 and headquartered in Willoughby Hills, Ohio, the company specializes in its proprietary platform technology known as Electrical Nerve Block. This technology is designed to eliminate chronic pain across various conditions, including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine. The Neuros Altius System, one of its key products, includes an implantable generator with an integrated rechargeable battery, a cuff electrode, and external devices, further demonstrating the company's commitment to advancing pain management solutions.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

Verix Health is a medical device company focused on creating a range of actively steerable surgical instruments designed for minimally invasive diagnosis and treatment of challenging lesions in hard-to-reach areas of the human body. Founded by Professor Mark Yim, PhD, in collaboration with PCI Ventures at the University of Pennsylvania, the company is incubated at the Pennovation Center in Philadelphia. Verix Health's innovative devices aim to enhance access and control during surgical procedures, allowing for precise targeting of tumors that are difficult to reach, thereby facilitating minimally invasive treatment options for patients with unfavorable tumor locations.

Founded in 2013, Bardy Diagnostics specializes in developing advanced cardiac monitoring devices. Its flagship product is the Carnation Ambulatory Monitor (CAM), a discreet and comfortable patch monitor designed to capture clear P-wave signals for accurate arrhythmia detection. The company also offers BDxCONNECT, a patient management system that aids clinical decision-making by providing easy access to CAM reports.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

Channel Medsystems, Inc. is a medical device company specializing in women’s healthcare technologies, particularly for endometrial ablation. Founded in 2009 and based in Emeryville, California, the company has developed an innovative cryothermic technology and a streamlined delivery system tailored for female patients and healthcare providers. Their devices integrate cryothermic energy into a self-contained, handheld unit, which eliminates the need for separate control units or additional capital equipment. Channel Medsystems aims to empower women to take control of their health journeys through its advanced cryotherapy solutions.

Neuros Medical, Inc. is a neuromodulation company dedicated to developing innovative therapies to address unmet medical needs for patients globally. Founded in 2008 and headquartered in Willoughby Hills, Ohio, the company specializes in its proprietary platform technology known as Electrical Nerve Block. This technology is designed to eliminate chronic pain across various conditions, including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine. The Neuros Altius System, one of its key products, includes an implantable generator with an integrated rechargeable battery, a cuff electrode, and external devices, further demonstrating the company's commitment to advancing pain management solutions.

Spirox, Inc. is a medical device company based in Menlo Park, California, that specializes in improving the quality of life for patients experiencing nasal obstruction due to nasal valve collapse (NVC). Founded in 2011 and formerly known as Nasoform LLC, Spirox has developed the LATERA absorbable nasal implant, which offers a minimally invasive solution for treating one of the most prevalent yet often overlooked causes of nasal obstruction. The LATERA implant is designed to address weakened lateral wall cartilage, providing ENT specialists and facial plastic surgeons with an effective option to alleviate nasal airway obstruction. As of 2017, Spirox operates as a subsidiary of Entellus Medical, Inc.

Channel Medsystems, Inc. is a medical device company specializing in women’s healthcare technologies, particularly for endometrial ablation. Founded in 2009 and based in Emeryville, California, the company has developed an innovative cryothermic technology and a streamlined delivery system tailored for female patients and healthcare providers. Their devices integrate cryothermic energy into a self-contained, handheld unit, which eliminates the need for separate control units or additional capital equipment. Channel Medsystems aims to empower women to take control of their health journeys through its advanced cryotherapy solutions.

Spirox, Inc. is a medical device company based in Menlo Park, California, that specializes in improving the quality of life for patients experiencing nasal obstruction due to nasal valve collapse (NVC). Founded in 2011 and formerly known as Nasoform LLC, Spirox has developed the LATERA absorbable nasal implant, which offers a minimally invasive solution for treating one of the most prevalent yet often overlooked causes of nasal obstruction. The LATERA implant is designed to address weakened lateral wall cartilage, providing ENT specialists and facial plastic surgeons with an effective option to alleviate nasal airway obstruction. As of 2017, Spirox operates as a subsidiary of Entellus Medical, Inc.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

Xlumena, Inc. is a medical technology company specializing in the development of image-guided therapeutic endoscopy products. Founded in 2008 and located in Mountain View, California, the company focuses on creating innovative solutions for gastrointestinal and biliary conditions. Its product offerings include the AXIOS Stent and Delivery System, which is designed for treating pancreatic pseudocysts, and the NAVIX Access Device, also targeting this condition. Additionally, Xlumena develops a self-expanding anchor stent for bile duct stenting, an integrated system for reliable pseudocyst drainage, and a solution for hiatal hernia repair performed through the gastrointestinal lumen. In 2015, Xlumena became a subsidiary of Boston Scientific Corporation, further enhancing its capabilities in the medical device field.

Channel Medsystems, Inc. is a medical device company specializing in women’s healthcare technologies, particularly for endometrial ablation. Founded in 2009 and based in Emeryville, California, the company has developed an innovative cryothermic technology and a streamlined delivery system tailored for female patients and healthcare providers. Their devices integrate cryothermic energy into a self-contained, handheld unit, which eliminates the need for separate control units or additional capital equipment. Channel Medsystems aims to empower women to take control of their health journeys through its advanced cryotherapy solutions.

Avedro, Inc. is a commercial-stage ophthalmic pharmaceutical and medical device company headquartered in Waltham, Massachusetts. The company specializes in developing and commercializing innovative products for treating corneal disorders, primarily focusing on corneal ectatic conditions and refractive issues. Avedro's proprietary Corneal Remodeling Platform includes the KXL and Mosaic systems, which utilize ultraviolet A (UVA) light in conjunction with riboflavin drug formulations for corneal cross-linking. This technology is aimed at strengthening and reshaping the cornea through minimally invasive and non-invasive outpatient procedures. Avedro has also introduced the Keraflex refractive correction procedure, a non-invasive technique for flattening the cornea without tissue removal. While Avedro primarily serves ophthalmologists, hospitals, and ambulatory surgery centers in the United States, it also markets its products internationally through medical device distributors. The company, originally named ThermalVision, Inc., was incorporated in 2002 and rebranded as Avedro in 2005. As of November 2019, Avedro operates as a subsidiary of Glaukos Corporation.

Avedro, Inc. is a commercial-stage ophthalmic pharmaceutical and medical device company headquartered in Waltham, Massachusetts. The company specializes in developing and commercializing innovative products for treating corneal disorders, primarily focusing on corneal ectatic conditions and refractive issues. Avedro's proprietary Corneal Remodeling Platform includes the KXL and Mosaic systems, which utilize ultraviolet A (UVA) light in conjunction with riboflavin drug formulations for corneal cross-linking. This technology is aimed at strengthening and reshaping the cornea through minimally invasive and non-invasive outpatient procedures. Avedro has also introduced the Keraflex refractive correction procedure, a non-invasive technique for flattening the cornea without tissue removal. While Avedro primarily serves ophthalmologists, hospitals, and ambulatory surgery centers in the United States, it also markets its products internationally through medical device distributors. The company, originally named ThermalVision, Inc., was incorporated in 2002 and rebranded as Avedro in 2005. As of November 2019, Avedro operates as a subsidiary of Glaukos Corporation.

Xlumena, Inc. is a medical technology company specializing in the development of image-guided therapeutic endoscopy products. Founded in 2008 and located in Mountain View, California, the company focuses on creating innovative solutions for gastrointestinal and biliary conditions. Its product offerings include the AXIOS Stent and Delivery System, which is designed for treating pancreatic pseudocysts, and the NAVIX Access Device, also targeting this condition. Additionally, Xlumena develops a self-expanding anchor stent for bile duct stenting, an integrated system for reliable pseudocyst drainage, and a solution for hiatal hernia repair performed through the gastrointestinal lumen. In 2015, Xlumena became a subsidiary of Boston Scientific Corporation, further enhancing its capabilities in the medical device field.

CardioMEMS is a medical device company specializing in wireless monitoring solutions for severe chronic cardiovascular conditions. Their proprietary technology involves miniature sensors implanted via minimally invasive procedures, transmitting vital data like cardiac output, blood pressure, and heart rate to enhance patient management, particularly for heart failure, hypertension, and aneurysms.

CardioMEMS is a medical device company specializing in wireless monitoring solutions for severe chronic cardiovascular conditions. Their proprietary technology involves miniature sensors implanted via minimally invasive procedures, transmitting vital data like cardiac output, blood pressure, and heart rate to enhance patient management, particularly for heart failure, hypertension, and aneurysms.

Interlace Medical, Inc. specializes in designing and developing medical devices tailored for interventional gynecologists. The company's primary focus is on creating innovative solutions for office-based procedures that address gynecological diseases and conditions that have historically necessitated surgical intervention in operating rooms. Among its notable products is the MyoSure hysteroscopic tissue removal system, which is specifically designed for the removal of submucosal fibroids and polyps. Through its advancements, Interlace Medical aims to enhance the efficiency and effectiveness of gynecological treatments, thereby improving patient outcomes.

TherOx, Inc., established in 1994 and headquartered in Irvine, California, is a privately-held medical device company focused on improving heart attack treatment standards. It specializes in developing dissolved oxygen delivery systems, notably its SuperSaturated Oxygen Therapy (SSO2), which involves creating supersaturated oxygenated blood using the TherOx DownStream system for delivery to coronary arteries. This therapy has shown promise beyond initial heart attack treatment, with potential applications in stroke, oncology, and wound care. As of June 18, 2019, TherOx operates as a subsidiary of ZOLL Medical Corporation. The company holds 20 issued patents, with more pending, reflecting its extensive research and development efforts.

Mako Surgical is a medical device company based in Florida, specializing in advanced robotic arm solutions and orthopedic implants for minimally invasive procedures, particularly in knee and hip surgeries. The company’s flagship offering, MAKOplasty, is a restorative surgical solution designed to assist orthopedic surgeons in treating early to mid-stage osteoarthritic conditions in patients. Mako Surgical's robotic arm interactive orthopedic system (RIO) features a tactile robotic arm and an integrated bone cutting instrument, providing pre-operative and intra-operative guidance to enhance surgical precision. This technology facilitates tissue-sparing bone removal and accurate implant insertion and alignment, ultimately improving patient outcomes. Founded in 2004, Mako Surgical has gained recognition in the medical technology field, having been named the fastest growing technology company by Deloitte and receiving multiple awards for customer excellence and innovation.

Altea Therapeutics Corporation develops and commercializes transdermal drug delivery systems. It offers PassPort patch, a skin patch that uses short bursts of focused thermal energy to create tiny channels in the surface of the skin and these channels permit the flow of proteins, peptides, carbohydrates, and small molecules into the body without the use of needles. The company also provides Transdermal vaccine patch, a delivery system for water-soluble drugs and proteins; disease prevention products; insulin skin patch, a non-injectable daily insulin product; and opioid patches that provide delivery of opioids and incorporates the layers of deterrents. Altea Therapeutics Corporation was formerly known as Altea Development Corporation. The company was founded in 1998 and is based in Atlanta, Georgia. As of May 9, 2012, Altea Therapeutics Corporation operates as a subsidiary of Nitto Denko Corp.

Mako Surgical is a medical device company based in Florida, specializing in advanced robotic arm solutions and orthopedic implants for minimally invasive procedures, particularly in knee and hip surgeries. The company’s flagship offering, MAKOplasty, is a restorative surgical solution designed to assist orthopedic surgeons in treating early to mid-stage osteoarthritic conditions in patients. Mako Surgical's robotic arm interactive orthopedic system (RIO) features a tactile robotic arm and an integrated bone cutting instrument, providing pre-operative and intra-operative guidance to enhance surgical precision. This technology facilitates tissue-sparing bone removal and accurate implant insertion and alignment, ultimately improving patient outcomes. Founded in 2004, Mako Surgical has gained recognition in the medical technology field, having been named the fastest growing technology company by Deloitte and receiving multiple awards for customer excellence and innovation.

Altea Therapeutics Corporation develops and commercializes transdermal drug delivery systems. It offers PassPort patch, a skin patch that uses short bursts of focused thermal energy to create tiny channels in the surface of the skin and these channels permit the flow of proteins, peptides, carbohydrates, and small molecules into the body without the use of needles. The company also provides Transdermal vaccine patch, a delivery system for water-soluble drugs and proteins; disease prevention products; insulin skin patch, a non-injectable daily insulin product; and opioid patches that provide delivery of opioids and incorporates the layers of deterrents. Altea Therapeutics Corporation was formerly known as Altea Development Corporation. The company was founded in 1998 and is based in Atlanta, Georgia. As of May 9, 2012, Altea Therapeutics Corporation operates as a subsidiary of Nitto Denko Corp.

TherOx, Inc., established in 1994 and headquartered in Irvine, California, is a privately-held medical device company focused on improving heart attack treatment standards. It specializes in developing dissolved oxygen delivery systems, notably its SuperSaturated Oxygen Therapy (SSO2), which involves creating supersaturated oxygenated blood using the TherOx DownStream system for delivery to coronary arteries. This therapy has shown promise beyond initial heart attack treatment, with potential applications in stroke, oncology, and wound care. As of June 18, 2019, TherOx operates as a subsidiary of ZOLL Medical Corporation. The company holds 20 issued patents, with more pending, reflecting its extensive research and development efforts.

Metra Biosystems specializes in developing and marketing diagnostic tools to detect and manage metabolic bone and joint diseases.